Post by Raghabendra kumar Mahato

As the European Hematology Association Congress 2026 comes to a close, I am deeply grateful to share two important milestones in my research journey. 📖 Publication in HemaSphere (Impact Factor 14.6,Top 5 hematology journal indeced Globally.) 📊 Poster Presentation at EHA 2026 1.𝐁𝐓𝐊𝐢-𝐅𝐢𝐫𝐬𝐭 𝐕𝐞𝐫𝐬𝐮𝐬 𝐕𝐞𝐧𝐞𝐭𝐨𝐜𝐥𝐚𝐱-𝐎𝐛𝐢𝐧𝐮𝐭𝐮𝐳𝐮𝐦𝐚𝐛-𝐅𝐢𝐫𝐬𝐭 𝐒𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 𝐢𝐧 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐋𝐲𝐦𝐩𝐡𝐨𝐜𝐲𝐭𝐢𝐜 𝐋𝐞𝐮𝐤𝐞𝐦𝐢𝐚 (𝐂𝐋𝐋): 𝐀 𝐏𝐫𝐨𝐩𝐞𝐧𝐬𝐢𝐭𝐲 𝐒𝐜𝐨𝐫𝐞-𝐌𝐚𝐭𝐜𝐡𝐞𝐝 𝐓𝐨𝐭𝐚𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 Using the TriNetX Global Collaborative Network comprising 171 healthcare organizations, our study evaluated more than 3,500 propensity-matched patients receiving two different frontline treatment sequencing strategies for CLL. The analysis demonstrated that overall survival, hospitalization, sepsis, atrial fibrillation, emergency department visits, pancytopenia, and advanced cellular therapy utilization were largely comparable between the two approaches. These findings suggest that treatment sequencing may be individualized according to patient characteristics, toxicity profiles, and clinical priorities without compromising long-term outcomes. Publication at the EHA 2026 2.𝑭𝑳𝑻3 𝑰𝒏𝒉𝒊𝒃𝒊𝒕𝒐𝒓𝒔 𝑷𝒍𝒖𝒔 𝑰𝒏𝒕𝒆𝒏𝒔𝒊𝒗𝒆 𝑪𝒉𝒆𝒎𝒐𝒕𝒉𝒆𝒓𝒂𝒑𝒚 𝒊𝒏 𝑵𝒆𝒘𝒍𝒚 𝑫𝒊𝒂𝒈𝒏𝒐𝒔𝒆𝒅 𝑭𝑳𝑻3-𝑴𝒖𝒕𝒂𝒕𝒆𝒅 𝑨𝒄𝒖𝒕𝒆 𝑴𝒚𝒆𝒍𝒐𝒊𝒅 𝑳𝒆𝒖𝒌𝒆𝒎𝒊𝒂 (𝑨𝑴𝑳): 𝑨 𝑺𝒚𝒔𝒕𝒆𝒎𝒂𝒕𝒊𝒄 𝑹𝒆𝒗𝒊𝒆𝒘 𝒂𝒏𝒅 𝑴𝒆𝒕𝒂-𝑨𝒏𝒂𝒍𝒚𝒔𝒊𝒔 Our systematic review synthesized contemporary evidence regarding the integration of FLT3 inhibitors with intensive chemotherapy in newly diagnosed FLT3-mutated AML. The accumulated evidence supports improved remission rates and survival outcomes compared with conventional chemotherapy alone, reinforcing the transformative role of targeted therapies in modern AML management. For me, these achievements represent far more than publications and presentations.They reflect the power of collaboration, curiosity, mentorship, and evidence-based medicine to advance patient care. As a medical student and researcher from Nepal,contributing to work presented and published alongside leading international investigators reminds me that impactful science is not defined by geography—it is defined by commitment, rigor,and a willingness to ask meaningful questions. I am sincerely grateful to my co-authors, mentors, collaborators,and the global hematology community for fostering an environment where young researchers can contribute to advancing knowledge and improving patient outcomes. The journey continues, and there is still much to learn, discover, and contribute. American Journal of Hematology / Oncology® Hematology-Oncology Associates of CNY The Cancer & Hematology Centers UT MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences Hematoonkologia.pl Szpital Uniwersytecki w Krakowie Onco-Hemato Hematology Professionals #EHA2026